Davide Leone & Partners Investment Company Llp Has Lowered Bristol Myers Squibb Co (BMY) Stake By $89.95 Million; Chimerix, Inc. (CMRX) Had 3 Bullish Analysts

February 19, 2018 - By wolcottdaily

Davide Leone & Partners Investment Company Llp decreased Bristol Myers Squibb Co (BMY) stake by 91.95% reported in 2017Q3 SEC filing. Davide Leone & Partners Investment Company Llp sold 1.43 million shares as Bristol Myers Squibb Co (BMY)’s stock declined 1.04%. The Davide Leone & Partners Investment Company Llp holds 125,000 shares with $7.97M value, down from 1.55M last quarter. Bristol Myers Squibb Co now has $112.58 billion valuation. The stock decreased 0.03% or $0.02 during the last trading session, reaching $68.96. About 10.55 million shares traded or 47.02% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 19, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.




Among 10 analysts covering Chimerix Inc (NASDAQ:CMRX), 3 have Buy rating, 3 Sell and 4 Hold. Therefore 30% are positive. Chimerix Inc had 20 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. As per Wednesday, February 14, the company rating was downgraded by JP Morgan. The firm earned “Neutral” rating on Tuesday, December 29 by JP Morgan. The company was downgraded on Wednesday, February 14 by J.P. Morgan. Citigroup initiated Chimerix, Inc. (NASDAQ:CMRX) on Thursday, September 3 with “Buy” rating. FBR Capital maintained Chimerix, Inc. (NASDAQ:CMRX) on Tuesday, February 23 with “Mkt Perform” rating. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 18. The stock of Chimerix, Inc. (NASDAQ:CMRX) has “Overweight” rating given on Tuesday, December 29 by Barclays Capital. The rating was maintained by Brean Capital on Thursday, August 6 with “Buy”. The company was maintained on Monday, December 28 by Piper Jaffray. See Chimerix, Inc. (NASDAQ:CMRX) latest ratings:

14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
02/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10 Initiates Coverage On

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Wednesday, August 16 with “Hold”. As per Monday, July 17, the company rating was maintained by Deutsche Bank. The firm earned “Overweight” rating on Thursday, February 15 by Morgan Stanley. Jefferies maintained the shares of BMY in report on Tuesday, March 15 with “Hold” rating. The firm earned “Hold” rating on Thursday, July 27 by Piper Jaffray. As per Friday, April 29, the company rating was maintained by Barclays Capital. Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Monday, July 17. Jefferies has “Buy” rating and $6300 target. Berenberg downgraded Bristol-Myers Squibb Company (NYSE:BMY) rating on Thursday, August 11. Berenberg has “Hold” rating and $70 target. The firm has “Buy” rating by Citigroup given on Wednesday, October 18. The firm earned “Hold” rating on Thursday, July 14 by Jefferies.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Wellington Shields Limited holds 41,600 shares or 0.35% of its portfolio. Lucas Management accumulated 67,386 shares or 3.85% of the stock. Benjamin F Edwards & Co Incorporated has invested 0.16% in Bristol-Myers Squibb Company (NYSE:BMY). Carnegie Capital Asset Mngmt Lc holds 0.63% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 84,284 shares. Fruth Inv Mgmt holds 0.58% or 19,733 shares. Spectrum Gp Inc, a Indiana-based fund reported 170 shares. Crawford Inv Counsel invested in 19,994 shares or 0.04% of the stock. Princeton Strategies Ltd Limited Liability Company holds 0.8% or 46,627 shares in its portfolio. Donaldson Lc holds 0.09% in Bristol-Myers Squibb Company (NYSE:BMY) or 13,824 shares. Smith Salley And Assocs holds 8,157 shares. 30,000 were accumulated by Granite Point Cap Mgmt L P. Blackrock holds 0.32% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 99.35 million shares. 24,550 were accumulated by Poplar Forest Cap. Stratford Consulting Ltd reported 3,210 shares stake. Monetary Mgmt Gru Incorporated holds 1.12% or 41,859 shares.

Since September 6, 2017, it had 1 buying transaction, and 2 selling transactions for $646,385 activity. Another trade for 5,300 shares valued at $335,172 was made by Lynch Thomas J. Jr. on Tuesday, December 12. 4,000 shares were bought by Samuels Theodore R. II, worth $249,187 on Friday, December 15. Another trade for 9,340 shares valued at $560,400 was made by Caldarella Joseph C on Wednesday, September 6.

Investors sentiment increased to 1.08 in 2017 Q3. Its up 0.24, from 0.84 in 2017Q2. It is positive, as 12 investors sold Chimerix, Inc. shares while 25 reduced holdings. 8 funds opened positions while 32 raised stakes. 33.85 million shares or 4.32% more from 32.45 million shares in 2017Q2 were reported. Renaissance Techs Ltd Liability Corp holds 0% or 193,960 shares. Wells Fargo Mn, California-based fund reported 53,326 shares. 580 are held by Jpmorgan Chase. Artal Grp invested in 500,000 shares or 0.05% of the stock. Granite Invest Ptnrs Limited Liability Corp invested 0.04% of its portfolio in Chimerix, Inc. (NASDAQ:CMRX). Glenmede Trust Na invested in 6,992 shares or 0% of the stock. Voya Inv Mgmt Lc has 29,203 shares for 0% of their portfolio. Great West Life Assurance Can reported 4,500 shares. Jacobs Levy Equity Mngmt Incorporated holds 0.02% or 154,408 shares in its portfolio. Ameritas Invest Partners stated it has 0% in Chimerix, Inc. (NASDAQ:CMRX). Alps Advsr reported 46,331 shares. California Employees Retirement Sys has invested 0% in Chimerix, Inc. (NASDAQ:CMRX). Nationwide Fund invested 0% in Chimerix, Inc. (NASDAQ:CMRX). Jfs Wealth Limited Liability Co reported 0% in Chimerix, Inc. (NASDAQ:CMRX). Metropolitan Life Communication reported 0% of its portfolio in Chimerix, Inc. (NASDAQ:CMRX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts